Calls for papers
-
Boston Scientific has acquired Asthmatx, the developer of a bronchial thermoplasty procedure marketed as an alternative to inhaled medications for the treatment of severe asthma for an upfront payment of $193.5 million and future payments… Read more . . .
-
Version 3.10 of Copley Scientific’s CITDAS inhaler testing software is now available, according to the company. The new version, available as a free upgrade for current CITDAS v3.00 users, includes automatic data importation from Waters… Read more . . .
-
Japan has approved Daiichi Sankyo’s Inavir laninamivir dry powder inhaler for the treatment of influenza. Treatment with Inavir requires only a single inhaled 40 mg dose. Read the Daiichi Sankyo Read more . . .
-
A survey sponsored by the University of Michigan’s C. S. Mott Children’s Hospital found support for regulation of e-cigarettes, with 82% of the US adults polled agreeing that the FDA should regulate the products. Approximately… Read more . . .
-
A PD study has shown no statistically significant difference in pulmonary artery pressure effects of Levadex inhaled dihydroergotamine (DHE) compared to placebo, according to MAP Pharmaceutical. The inhaled formulation had a smaller effect on pulmonary… Read more . . .
-
Prosonix has announced the availability of a new co-crystal development and processing service using its ultrasound technology for the manufacture of co-crystal APIs for inhalation products. According to the company, the process creates co-crystals with… Read more . . .
-
According to Archimedes Pharma, the European Commission has granted marketing authorization for the company’s PecFent fentanyl nasal spray for the treatment of breakthrough pain in adult cancer patients. Archimedes submitted an NDA for the product… Read more . . .
-
Quintiles has announced that it will provide commercialization services to Pharmaxis for the launch of Pharmaxis’s Bronchitol mannitol DPI for the treatment of Cystic Fibrosis. Bronchitol has received orphan drug status in both Europe and… Read more . . .
-
Cypress Bioscience of San Diego, California has aquired worldwide licensing rights for Alexza Pharmaceutical’s Staccato Nicotine inhaler for smoking cessation. Alexza will receive $5 million up front, with another $1 million due upon meeting preclinical… Read more . . .
-
Skye Pharma says that it understands why Abbot has decided to return US marketing rights for the Flutiform formoterol fluticasate MDI given the issues raised by the US FDA concerning approval of the drug. According… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland